Panel recommendations for MDS/MPN with SF3B1 mutation and thrombocytosis (WHO)/MDS/MPN with thrombocytosis and SF3B1 mutation (ICC) and MDS/MPN with ring sideroblasts and thrombocytosis, NOS (ICC only)
| Disease . | Panel recommendations . |
|---|---|
| MDS/MPN with SF3B1 mutation and thrombocytosis (WHO)/MDS/MPN with thrombocytosis and SF3B1 mutation (ICC) and MDS/MPN with ring sideroblasts and thrombocytosis, NOS (ICC only) | Transplant should be considered in high-risk eligible patients (eg, refractory anemia, adverse cytogenetics, and/or presence of ASXL1 or SETBP1 mutations) in both MDS/MPN with thrombocytosis with or without SF3B1 mutation, with a prompt donor search It is recommended that standard guidelines for MDS pertaining to transplant platform are applied |
| Disease . | Panel recommendations . |
|---|---|
| MDS/MPN with SF3B1 mutation and thrombocytosis (WHO)/MDS/MPN with thrombocytosis and SF3B1 mutation (ICC) and MDS/MPN with ring sideroblasts and thrombocytosis, NOS (ICC only) | Transplant should be considered in high-risk eligible patients (eg, refractory anemia, adverse cytogenetics, and/or presence of ASXL1 or SETBP1 mutations) in both MDS/MPN with thrombocytosis with or without SF3B1 mutation, with a prompt donor search It is recommended that standard guidelines for MDS pertaining to transplant platform are applied |